IMR Press / RCM / Volume 24 / Issue 3 / DOI: 10.31083/j.rcm2403086
Open Access Review
Sex-Specific Thresholds for Cardiac Biomarkers—We Need to Move Forward
Show Less
1 Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA
2 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
*Correspondence: Jaffe.Allan@mayo.edu (Allan S. Jaffe)
Rev. Cardiovasc. Med. 2023, 24(3), 86; https://doi.org/10.31083/j.rcm2403086
Submitted: 20 July 2022 | Revised: 11 February 2023 | Accepted: 13 February 2023 | Published: 8 March 2023
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract

Cardiovascular biomarkers play a major diagnostic role for cardiologists. Different biomarkers provide different insights into a variety of cardiovascular conditions and in doing so they improve diagnosis and management. Often, these biomarkers are deployed without carefully evaluating the use of sex-specific cut off values. It is now becoming apparent that the use of such cut off values can improve prognostication and discrimination in some clinical situations. This review paper will focus on the data indicating that there is benefit to the use of sex-specific thresholds. It should be clear that these thresholds will vary depending on the analyte being measured and the specific clinical indication for which the patients are being evaluated; and sex-specific cut off values may be important in some situations but not others. Nonetheless, it is now clear that when evaluating sex-specific cut off values, one often finds benefit. We will highlight these situations using specific cardiac biomarkers as examples.

Keywords
sex
troponin
natriuretic peptides
ST2
galectin
Share
Back to top